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Purpose: Upfront systemic chemotherapy with target agents has been recommended for patients with stage IV colon can-
cer. Some with partial response are considered for curative resection. There is high risk of developing postoperative com-
plications following upfront systemic chemotherapy. We aimed to evaluate short-term perioperative outcomes of curative 
surgery after upfront chemotherapy in comparison with upfront surgery in patients with metastatic colon cancer.
Methods: Between January 2010 and October 2015, 146 patients (80 in the surgery first group, 66 in the upfront chemo-
therapy group) who underwent surgical resection before or after systemic chemotherapy for metastatic colon cancer were 
included in the present study. All decisions for treatment were made through a multidisciplinary team. Postoperative clin-
ical outcomes and complications were analyzed to compare the groups.
Results: There was no difference between the 2 groups in terms of postoperative clinical outcomes. Overall complication 
rates were not different between the groups (surgery first group: 46.3% vs. upfront chemotherapy group: 60.6%; P = 
0.084). When classified according to the Clavien-Dindo method, there was no difference between the 2 groups in terms of 
major complications (grade 3 or more) (surgery first group: 18.9% vs. upfront chemotherapy group: 27.5%; P = 0.374).
Conclusion: There was no significant increase in major postoperative complications in metastatic colon cancer patients 
who received upfront chemotherapy followed by curative surgery. Careful patient selection and treatment planning are 
important.
Keywords: Colonic neoplasms; Neoplasm metastasis; Antineoplastic agents; Postoperative complications
INTRODUCTION
At the time of diagnosis, approximately 20%–25% of colorectal 
cancer patients already have metastasis. In these individuals, the 
treatment strategy will be palliative or curative according to dis-
ease status [1]. In recent years, even unresectable metastatic le-
sions can be resected if the tumor response is favorable to previ-
ous systemic chemotherapy. Adam et al. [2] found that, among 
1,104 initially unresectable colorectal liver metastases patients, 
138 with good response (12.5%) underwent hepatic resection af-
ter an average of 10 sessions of chemotherapy, and a 5-year sur-
vival rate of 33% was achieved versus a rate of 5% in patients who 
did not undergo resection. In some cases of resectable metastasis, 
upfront systemic chemotherapy is recommended for various rea-
sons. First, upfront chemotherapy can play a role as an in vivo 
chemosensitivity assay and can be used in conjunction with meta-
bolic imaging (e.g., fluorodeoxyglucose - positron emission to-
mography) to reflect differences in the biologic tumor associated 
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with various responses. Further, chemically reducing the tumor 
prior to surgery can lessen the frequency of tumor cell shedding 
during surgery and improve the rate of R0 resection [3]. The goal 
of systemic chemotherapy for these patients is to cure the disease 
or prolong survival and maintain quality of life as long as possible 
[1].
Several developments have improved systemic chemotherapy in 
patients with metastatic colorectal cancer. Introduction of combi-
nation chemotherapy protocols and addition of new biological 
target agents such as bevacizumab and cetuximab have led to sig-
nificant advances in tumor response after chemotherapy for met-
astatic colorectal cancer patients [4]. In particular, the target agent 
acts on a specific molecule of cancer cells to exert its anticancer 
effect, which is less harmful to normal cells than other types of 
chemotherapy and has the potential to cause fewer side effects. In 
a recent review, addition of a biologic agent to conventional che-
motherapy increased the rate of conversion to a resectable state in 
patients with unresectable metastatic colorectal cancer [5].
However, systemic chemotherapy alone rarely cures metastatic 
colorectal cancer. In patients with metastatic colorectal cancer, 
curative resection (R0) is the only therapeutic option for long-
term survival [6]. In addition, in potentially resectable stage IV 
colon cancer patients with good tumor response after upfront 
chemotherapy, R0 resection can be achieved [7].
However, administration of chemotherapy may lead to higher 
perioperative morbidity. Oxaliplatin is related to sinusoidal liver 
lesions, and irinotecan is related to steatohepatitis. We also do not 
yet fully understand the potential toxicity of antiangiogenesis 
agents like bevacizumab [8]. In addition, combined resection for 
primary tumor and metastasis usually requires many surgical 
procedures and long operation times. Furthermore, patients may 
receive a long duration of upfront chemotherapy or chemoradia-
tion therapy. These concerns may place a burden on the surgeon 
in making decisions about the operation regarding timing of sur-
gery after upfront chemotherapy. Additionally, the optimal timing 
of surgery and cessation of systemic chemotherapy prior to sur-
gery are not well-established.
The aim of our study was to evaluate perioperative clinical 
short-term outcomes of curative surgery after upfront chemo-
therapy for patients with metastatic colon cancer.
METHODS
Patients
We retrospectively analyzed 146 patients diagnosed with meta-
static colon cancer who underwent surgical resection before or 
after systemic chemotherapy at Yonsei University Severance Hos-
pital, South Korea, between January 2010 and October 2015. Pa-
tients with peritoneal metastasis were excluded from the present 
study. We collected information on all study participants from 
their medical records and divided them into the 2 groups: the sur-
gery first group of 80 initially ‘resectable’ patients who underwent 
surgical resection followed by adjuvant chemotherapy, and the 
upfront chemotherapy group of 66 initially ‘potentially resectable’ 
or ‘unresectable’ patients who underwent upfront chemotherapy 
followed by surgical resection. We retrospectively compared these 
2 groups. To evaluate the distribution, number, and size of the le-
sions before initiation of treatment, image examinations of the 
thoracic, abdominal, and pelvic areas were performed. All deci-
sions for treatment were made by a multidisciplinary team com-
posed of surgeons, medical oncologists, radiation oncologists, and 
radiologists. To achieve improved accuracy in decision-making 
and in treatment plans as well as better surgical and oncologic out-
comes and increased patient satisfaction, all patients were evalu-
ated with consideration of the various aspects during a multidisci-
plinary team conference. Resectability of the primary tumor and 
metastatic lesions was mainly assessed via reinterpretation by and 
discussion of the imaging results by radiologists and surgeons. We 
initially identified the primary tumor as ‘unresectable’ when it 
showed extensive involvement of a major structure like the vena 
cava, superior mesenteric vessel, pancreas, or duodenum. For he-
patic metastatic lesions, when the remnant parenchyma of the 
liver was expected to be less than 30% of the total volume after re-
section, we defined this as ‘unresectable.’ When resection was 
needed rather than lobectomy, or if a patient had insufficient re-
spiratory function, we categorized the cancer as ‘unresectable’ 
lung metastasis [9]. For patients with ‘unresectable’ or ‘potentially 
resectable’ tumors, a chemotherapeutic agent was administered 
according to the guidelines of National Health Insurance of Ko-
rea. The physician chose the target agent in consultation with the 
patient according to the results of a K-ras mutation test. Cetux-
imab or bevacizumab was used for patients without the K-ras 
mutation, and bevacizumab was chosen for patients with the K-
ras mutation. During patient follow-up, imaging studies were re-
peated to investigate treatment response and resectability. Ac-
cording to the RECIST (response evaluation criteria in solid tu-
mor) [10], we defined a ‘partial response’ as a ≥50% decrease in 
tumor size on imaging studies. ‘Progressive disease’ was defined 
as a >25% increase in tumor size or detection of newly developed 
lesions. Otherwise, cases were defined as ‘stable disease.’ In this 
study, 33 patients (50%) showed ‘partial response,’ 32 patients 
(48.5%) had ‘stable disease,’ and only 1 patient (1.5%) showed 
‘progressive disease’ based on one newly developed liver metasta-
sis on imaging during follow-up. When a tumor converted to re-
sectable during follow-up, we considered surgery with a curative 
intent. This study was approved by the Institutional Review Board 
(IRB) of Severance Hospital Yonsei University Health System (IRB 
No. 2018-0566-001). The need for informed consent was waived 
by the IRB.
Clinical variables
Data on patient and tumor characteristics, upfront chemotherapy 
regimens, operative factors, and clinical factors related to postop-
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tumor characteristics comprised age; sex; weight; height; body 
mass index (BMI); American Society of Anesthesiologists (ASA) 
physical status classification; primary colon cancer location; organ 
with metastasis; tumor, lymph node (N), and metastasis (M) 
stages in accordance with the American Joint Committee on Can-
cer staging [11]; and histology of the tumor. Upfront chemother-
apy regimens were evaluated for agents used, duration and cycles 
of therapy, and time from completion of chemotherapy to surgery. 
Operative variables were surgical approach method, surgical pro-
cedures for primary colon cancer, surgical procedures for meta-
static lesions, and open conversion.
Operative management
All patients underwent primary resection of colon cancer accord-
ing to location, and resection of metastatic lesions was performed. 
Some patients underwent a staged operation following consider-
ation of the location and size of the metastatic lesions and the co-
morbidity and condition of the patient. In patients with more 
than 2 organ metastases, simultaneous resection was performed 
when possible. However, in most cases, a staged operation was 
performed considering the width of resection. Meanwhile, if it 
was impossible to perform resection or if the risk was greater than 
the anticipated benefit, a second operation was not performed.
Postoperative outcomes
Postoperative short-term clinical outcomes of time to first fluid 
intake, time to first flatus, and length of hospital stay were evalu-
ated. Postoperative complications were evaluated and graded us-
ing the Clavien-Dindo classification system [12], a previously de-
fined grading system for surgical complications.
Statistical analysis
We performed all statistical analyses using IBM SPSS Statistics 
ver. 23.0 (IBM Co., Armonk, NY, USA). Categorical variables 
were analyzed using the chi-square or Fisher exact test, while con-
tinuous variables were analyzed using Student t-test or Mann-
Whitney U-test. A significance level (P-value) less than 0.05 was 
considered statistically significant.
RESULTS
Patient and tumor characteristics
Patient and tumor characteristics are listed in Table 1. There were 
more T4 patients in the Surgery first group (surgery first group: 
33.8% vs. upfront chemotherapy group: 6.1%) and more T3 pa-
tients in the upfront chemotherapy group (surgery first group: 
61.3% vs. upfront chemotherapy group: 83.3%), possibly due to 
tumor shrinkage caused by upfront chemotherapy. In compari-
son, age, sex, weight, height, BMI, ASA physical status classifica-
tion, primary tumor site, metastasis site, N stage, M stage, and 
histology did not differ significantly between the 2 groups. In 
both groups, the most frequent primary colon cancer site was the 








Age (yr) 61.31 ± 11.91 59.00 ± 9.20 0.199
Sex 0.937
   Male 49 (61.3) 40 (60.6)
   Female 31 (38.8) 26 (39.4)
Weight (kg) 62.37 ± 9.88 61.56 ± 11.26 0.647
Height (cm) 162.87 ± 8.08 161.95 ± 7.09 0.471
Body mass index (kg/m2) 23.41 ± 2.66 23.34 ± 3.17 0.879
ASA PS classification ≥ III 14 (17.5) 16 (24.2) 0.316
K-ras status 0.031
   Wild type 22 (27.5) 32 (48.5)
   Mutant 28 (35.0) 15 (22.7)
   Unknown 30 (37.5) 19 (28.8)
Primary tumor site 0.605
   Cecum 3 (3.8) 2 (3.0)
   Ascending colon 19 (23.8) 12 (18.2)
   Hepatic flexure 5 (6.3) 1 (1.5)
   Transverse colon 4 (5.0) 4 (6.1)
   Splenic flexure 1 (1.3) 0 (0)
   Descending colon 7 (8.8) 10 (15.2)
   Sigmoid colon 40 (50.0) 37 (56.1)
   Ascending colon + sigmoid colon 1 (1.3) 0 (0)
Metastatic site
   Liver 74 (92.5) 65 (98.5) 0.128
   Lung 10 (12.5) 11 (16.7) 0.475
   Para-aortic lymph node 5 (6.3) 8 (12.1) 0.215
   Adrenal gland 0 (0) 1 (1.5) 1
   Diaphragm 1 (1.3) 0 (0) 1
T stage <0.001 
   T0, no residual cancer 1 (1.3) 4 (6.1)
   T1 0 (0) 0 (0)
   T2   3 (3.8) 3 (4.5)
   T3 49 (61.3) 55 (83.3)
   T4a 21 (26.3) 4 (6.1)
   T4b 6 (7.5) 0 (0)
N stage 0.43
   N0 19 (23.8) 16 (24.2)
   N1a 15 (18.8) 10 (15.2)
   N1b 20 (25.0) 20 (30.3)
   N1c 3 (2.2) 1 (1.5)
   N2a 9 (11.3) 13 (19.7)
   N2b 14 (17.5) 6 (9.1)
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sigmoid colon (surgery first group: 50.0% vs. upfront chemother-
apy group: 56.1%), and the most frequent metastatic organs were 
the liver and lungs (surgery first group: 92.5% and 12.5%, respec-
tively, vs. upfront chemotherapy group: 98.5% and 16.7%).
Upfront chemotherapy was administered to all upfront chemo-
therapy group patients (Tables 2, 3). Combination therapies con-
taining oxaliplatin or irinotecan (folinic acid + 5-fluorouracil + 
oxaliplatin [FOLFOX]; capecitabine + oxaliplatin [XELOX]; or 
folinic acid + 5-fluorouracil + irinotecan [FOLFIRI]) were 
adapted. Forty-four patients received the following target agents: 
bevacizumab (n = 23; 52.3%), cetuximab (n = 20; 45.5%), and 
aflibercept (n = 1; 2.3%). The median duration of upfront chemo-
therapy was 3 months (range, 0–32 months), and the median cy-
cle number for chemotherapy was 6 (range, 2–46 cycles). Addi-
tionally, the median time interval from completion of upfront 
chemotherapy and combined surgery was 6.4 weeks (range, 3.7–
57 weeks). In patients who received bevacizumab, the median 
chemotherapy duration was 2 months (range, 1–32 months), the 
median number of chemotherapy cycles was 6 (range, 4–46 cy-
cles), and the median time interval for completion of chemother-
apy and surgery was 6.8 weeks (range, 4–35 weeks). Because of 
the high risk of recurrence, systemic chemotherapy was per-
formed in both groups after surgery.
Operative management
All patients underwent combined surgery for primary tumor and 
metastatic lesions (Table 4). Open surgery was most common in 
both groups (surgery first group: 60% vs. upfront chemotherapy 
group: 87.9%). In the surgery first group, more laparoscopic sur-
gery was performed (surgery first group: 40% vs. upfront chemo-
therapy group: 9.1%). Conversion rates between the 2 groups 
were not significantly different (surgery first group: 0% vs. upfront 
chemotherapy group: 3%). Hepatic resections were classified ac-
cording to the segmental anatomy of the liver as defined by 
Couinaud [13]. We defined major liver resection as removal of 4 
or more liver segments, and this type was performed more often 
in the upfront chemotherapy group (surgery first group: 8.1% vs. 
upfront chemotherapy group: 21.5%). In surgery for lung metas-
tasis, an initial combined operation was more common in the 
surgery first group (surgery first group: 70% vs. upfront chemo-
therapy group: 9.1%). Meanwhile, a staged operation or no resec-
tion was performed in some cases based on the distribution of le-
sions or comorbidity of the patient. For liver metastasis, 5 staged 
liver resections were performed (surgery first group: 1.4% vs. up-
front chemotherapy group: 6.2%). For lung metastasis, 7 staged 









   M1a 66 (82.5) 47 (71.2)
   M1b 14 (17.5) 19 (28.8)
Histology 0.372
   Well-differentiated 3 (3.8) 4 (6.1)
   Moderately differentiated 74 (92.5) 59 (89.4)
   Poorly differentiated 1 (1.3) 3 (4.5)
   Mucinous 2 (2.5) 0 (0)
Values are presented as mean ± standard deviation or number (%).
ASA PS, American Society of Anesthesiologists physical status.
Table 1. Continued
Table 2. Details of chemotherapy (n = 66)
Variable Value
Regimen of upfront chemotherapy
   FOLFOXa 38 (57.6)
   FOLFIRIb 27 (40.9)
   XELOXc 1 (1.5)
Use of molecular target agent 44 (66.7)
   Bevacizumab 23 (52.3)
   Cetuximab 20 (45.5)
   Aflibercept 1 (2.3)
Duration of chemotherapy (mo) 3 (0–32)
Time interval between chemotherapy and surgery (wk) 6.4 (3.7–57)
Cycles of chemotherapy 6 (2–46)
Values are presented as number (%) or median (range).
aFOLFOX = folinic acid + 5-fluorouracil + oxaliplatin. bFOLFIRI = folinic acid + 
5-fluorouracil + irinotecan. cXELOX = capecitabine + oxaliplatin.








Regimen of adjuvant chemotherapy <0.001
   FOLFOXa 65 (81.3) 32 (48.5)
   FOLFIRIb 3 (3.8) 29 (43.9)
   XELOXc 3 (3.8) 1 (1.5)
   FLd 1 (1.3) 0 (0)
   No adjuvant chemotherapy 8 (10.0) 4 (6.1)
Use of molecular target agent <0.001
   Cetuximab 1 (1.3) 15 (23.1)
   Bevacizumab 9 (11.4) 17 (26.2)
   No target agent 70 (87.5) 34 (51.5)
Cycles of chemotherapy 12 (0–12) 6 (0–16) <0.001
Values are presented as number (%) or median (range).
aFOLFOX = folinic acid + 5-fluorouracil + oxaliplatin. bFOLFIRI = folinic acid + 
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group (surgery first group: 0% vs. upfront chemotherapy group: 
63.6%). However, in 6 additional cases, planned staged resection 
for lung metastasis could not be performed due to poor patient 
condition and progression of metastasis (surgery first group: 30% 
vs. upfront chemotherapy group: 27.2%). All patients who experi-
enced metastasis to para-aortic lymph nodes underwent curative 
para-aortic lymph node dissection.
 
Postoperative outcomes
There was no difference between the 2 groups in postoperative 
clinical course (Table 5). The median length of postoperative care 
was 10 days (range, 5–77 days) in the surgery first group and 12 
days (range, 4–47 days) in the upfront chemotherapy group. A to-
tal of 58 postoperative complications developed in 37 patients 








Open conversion 0 (0) 2 (3.0) 0.203
Surgical approach <0.001
   Open 48 (60.0) 58 (87.9)
   Laparoscopic 32 (40.0) 6 (9.1)
   Robotic 0 (0) 2 (3.0)
Simultaneous resection 76 (95.0) 52 (78.8) 0.003
Staged resection for metastasis 1 (1.3) 11 (16.7) 0.001
Failed staged resection for  
metastasis
3 (3.8) 3 (4.5) 1.000
Surgery for primary tumor 0.218
   Anterior resection 40 (50.0) 37 (56.1)
   Right hemicolectomy 29 (36.3) 16 (24.2)
   Left hemicolectomy 8 (10.0) 12 (18.2)
   S egmental resection of  
transverse colon    
1 (1.3) 1 (1.5)
   R ight hemicolectomy + anterior 
resection
2 (2.5) 0 (0)
Surgery for liver metastasis <0.001
   M ajor liver resection  
(≥4 segments)
6 (8.1) 14 (21.5)
   M inor liver resection  
(<4 segments)   
25 (33.7) 31 (47.7)
   Wedge resection or RFA only 42 (56.7) 16 (24.6)
   Staged resection 1 (1.4) 4 (6.2)
Surgery for lung metastasis 0.008
   Wedge resection under VATS 7/10 (70.0) 1/11 (9.1)
   No resection 3/10 (30.0) 3/11 (27.2)
   Staged resection 0/10 (0) 7/11 (63.6)
Values are presented as number (%).
RFA, radiofrequency ablation; VATS, video-assisted thoracic surgery.








Time to first fluid intake (day) 2 (1–25) 2 (1–6) 0.570
Time to first flatus (day) 4 (1–9) 4 (1–7) 0.770
Length of hospital stay (day) 10 (5–77) 12 (4–47) 0.470
Reoperation 1 (1.3) 1 (1.5) 1.000
Complications 37 (46.3) 40 (60.6) 0.084
Fever 15 (18.8) 20 (30.3) 0.104
Ascites 2 (2.5) 10 (15.2) 0.006
Chyle leakage 3 (3.8) 4 (6.1) 0.701
Ileus 14 (17.5) 8 (12.1) 0.366
Cardiac 0 (0) 2 (3) 0.203
Pulmonary 8 (10.0) 16 (24.2) 0.021
Urinary tract infection 0 (0) 1 (1.5) 0.452
Voiding difficulty 3 (3.8) 2 (3.0) 1.000
Renal 1 (1.3) 1 (1.5) 1.000
Delirium 1 (1.3) 1 (1.5) 1.000
Bleeding 0 (0) 1 (1.5) 0.452
Anastomotic leakage 1 (1.3) 2 (3.0) 0.590
Bile leakage 0 (0) 2 (3.0) 0.203
Superficial SSI 6 (7.5) 7 (10.6) 0.512
Organ/space SSI 2 (2.5) 4 (6.1) 0.410
Life-threatening complication  
requiring ICU management (G≥IV)
2 (2.5) 1 (1.5) 1.000
Reoperation due to anastomotic 
leakage
1 (1.3) 0 (0)
Reoperation due to bile leakage 0 (0) 1 (1.5)
Septic pneumonia 1 (1.3) 0 (0)
Clavien-Dindo classification 0.263
   I 3 (8.1) 6 (15.0)
   II 27 (72.9) 23 (57.5)
   IIIA 5 (13.5) 10 (25.0)
   IIIB 0 (0) 0 (0)
   IVA 1 (2.7) 1 (2.5)
   IVB 0 (0) 0 (0)
   V 1 (2.7) 0 (0)
Total 37 40
Major complication (G≥IIIA) 7 (18.9) 11 (27.5) 0.374
Values are presented as median (range) or number (%).
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(46.3%) in the surgery first group versus 82 postoperative compli-
cations in 40 patients (60.6%) in the upfront chemotherapy group 
(Table 5). However, there was no significant difference in overall 
complication rate between the 2 groups (surgery first group: 
46.3% vs. upfront chemotherapy group: 60.6%; P = 0.084). There 
was a notable difference in incidence of postoperative ascites (sur-
gery first group: 2.5% vs. upfront chemotherapy group: 15.2%; P 
= 0.006) and pulmonary complications (surgery first group: 10% 
vs. upfront chemotherapy group: 24.2%; P = 0.021), as both oc-
curred more often in the upfront chemotherapy group. Con-
versely, however, there was no difference between the 2 groups in 
terms of surgical site infection, bowel anastomotic leakage or bile 
leakage, or postoperative bleeding after surgery. In the upfront 
chemotherapy group, there was no bleeding or anastomotic leak-
age in any patient who received bevacizumab. There was no dif-
ference between the 2 groups when classified according to the 
Clavien-Dindo method (P = 0.263). There was no difference be-
tween the 2 groups in terms of major complications of grade III 
or higher (surgery first group: 18.9% vs. upfront chemotherapy 
group: 27.5%; P = 0.374). There was one case that needed inten-
sive care unit (ICU) admission following reoperation in both 
groups (surgery first group: 1.3% vs. upfront chemotherapy 
group: 1.5%). Reoperation was performed due to bowel anasto-
motic leakage in the surgery first group and due to bile leakage in 
the upfront chemotherapy group. One patient in the surgery first 
group died within 30 days of surgery after ICU care due to post-
operative renal failure and pulmonary sepsis.
DISCUSSION
Although metastatic colorectal cancer is generally incurable, re-
section of oligometastatic disease has curative potential [14]. Fur-
thermore, with the development of systemic chemotherapy, pa-
tients with ‘unresectable’ or ‘potentially resectable’ metastatic 
colorectal cancer are more likely to undergo surgical resection 
following upfront chemotherapy. This conversion therapy has 
been the subject of recent attention.
It may be natural for surgical oncologists to actively consider 
surgical resection for patients with ‘unresectable’ or ‘potentially 
resectable’ metastatic colorectal cancer. However, with extensive 
surgical resection and toxicity of systemic chemotherapy, it may 
be difficult to make aggressive decisions due to concerns about 
patient recovery after surgery. In addition, the optimal timing of 
appropriate surgery and of preoperative chemotherapy discontin-
uation have not yet been established.
To alleviate these concerns, it is necessary to determine whether 
preoperative chemotherapy leads to substantially increased post-
operative complications in patients who receive upfront chemo-
therapy followed by surgical resection. Several studies have re-
cently reported on the practicality of upfront chemotherapy in 
unresectable metastatic colorectal cancer patients [2, 5, 15-17], 
finding an improvement of resectability after upfront chemother-
apy in patients with metastatic colorectal cancer, with most proce-
dures performed in patients with liver metastasis. None of the 
studies focused on short-term outcomes in patients with meta-
static colorectal cancer who underwent surgery after upfront che-
motherapy. Thus, the present study has several strengths. This 
study was performed only in patients with solid organ metastatic 
colorectal cancer and those with peritoneal metastasis. Chemo-
therapeutic agents used in treatment were modern protocols, re-
flecting the use of current standards of practice. Furthermore, this 
study specifically investigated complications known to be associ-
ated with chemotherapeutic agents.
In this investigation, we reviewed postoperative clinical course 
and complications in patients who underwent surgical resection 
after upfront chemotherapy. We compared the results obtained 
with those of patients who underwent surgical resection first and 
investigated whether there were any substantive differences be-
tween the 2 groups. In terms of postoperative short-term clinical 
outcomes, there was no difference between the 2 groups. Postop-
erative complications developed in 46.3% patients in the surgery 
first group and 60.6% patients in the upfront chemotherapy 
group. Most of the complications were minor, and there was no 
difference between the 2 groups in grade III or more major com-
plications (surgery first group: 18.9% vs. upfront chemotherapy 
group: 27.5%; P = 0.374).
It is well-known that oxaliplatin increases the risk of sinusoidal 
obstruction syndrome [18]. A recent publication from Volk et al. 
[19] demonstrated that preoperative administration of bevaci-
zumab is associated with a strong reduction of total sinusoidal 
obstruction syndrome incidence. In that report, they also found 
that, while there was no difference in perioperative morbidity and 
mortality, there was a significant increase in wound complications 
in patients who received bevacizumab. In addition, a study by 
Vauthey et al. [20] revealed an increase in postoperative morbid-
ity rates in patients who developed steatohepatitis. In their study, 
although there was no association between type of chemotherapy 
and postoperative complications, there was a trend toward in-
creased postoperative morbidity in patients who underwent a 
longer duration of chemotherapy. Importantly, in this study, there 
was no significant increase in hepatobiliary or wound complica-
tions, bowel anastomotic leakage, or postoperative bleeding in pa-
tients in the upfront chemotherapy group. Although the upfront 
chemotherapy group had a higher incidence of postoperative as-
cites, these patients were more unresectable than those in the sur-
gery first group due to the presence of more advanced liver meta-
static lesions at the time of diagnosis. This led to more major liver 
resection after chemotherapy compared to patients in the surgery 
first group. Furthermore, in all cases, ascites was well-controlled 
with diuretic use alone. In our study, there was no increase in 
liver-related complications, especially in the upfront chemother-
apy group. This occurrence may be due to the beneficial effects of 
preoperative bevacizumab administration mentioned by Volk et 
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care and surgical techniques. In this regard, further investigations 
will be needed. In our study, major liver resection (i.e., involving 
more than 4 segments) was performed in 21.5% of the upfront 
chemotherapy group. In 4 patients, the associating liver partition 
and portal vein ligation in staged hepatectomy approach were 
performed in relation to the extent of hepatic metastasis. There 
were no liver-related complications noted in our study.
There was no bleeding or anastomotic leakage in patients who 
received bevacizumab. This finding may support the idea that 
there is no need to delay surgery due to concern for toxicity 
caused by chemotherapy or the postoperative bleeding or anasto-
motic leakage known to be increased by bevacizumab.
In our study, upfront chemotherapy did not significantly in-
crease postoperative complications. In particular, the incidence of 
specific complications known to be increased by chemotherapy 
was not substantially greater. These results were possible because 
of careful patient selection and appropriate treatment planning 
through a multidisciplinary team approach.
Our study has several limitations to consider. Since this study is 
a retrospective analysis of a single institution’s experience with a 
small number of patients, we cannot make definitive conclusions 
about the safety and feasibility of upfront chemotherapy. In addi-
tion, it is difficult to assess the number and severity of complica-
tions correctly in a retrospective study. Furthermore, there is con-
troversy regarding the definition of resectability. Although the 
treatment plan was chosen by a multidisciplinary team approach, 
without clear criteria, we determined resectability based on extent 
of metastatic disease and functional reserve of the remnant organ 
region. However, this study addresses the simple but important 
topic of evaluation of the association between upfront chemo-
therapy and postoperative morbidity in patients with metastatic 
colon cancer and may be helpful in decision-making for patients 
who require surgery after upfront chemotherapy.
In this study, we demonstrated that postoperative complications 
were not particularly increased in metastatic colon cancer patients 
who received upfront chemotherapy followed by curative surgery. 
There was no significant increase in hepatotoxicity, anastomotic 
leakage, or postoperative bleeding complications known to be as-
sociated with systemic chemotherapy. In these patients, focusing 
on the toxicity of chemotherapy should not interfere with the sur-
gical decision in cases where surgery is necessary. Upfront che-
motherapy followed by curative surgery in well-selected meta-
static colon cancer patients is a possible treatment option in terms 
of safety and feasibility. Careful patient selection and treatment 
planning are important, including consideration of patient co-
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